A Randomized, Active-Control Phase II Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection.
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2012
At a glance
- Drugs Bavituximab (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 03 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 03 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Dec 2011 Full results to be presented at a medical conference in 2012, as reported in a Peregrine Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History